查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714237

细胞激素市场－全球产业规模、份额、趋势、机会和预测，按细胞激素类型、治疗应用、地区和竞争细分，2020-2030 年

Cytokine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cytokine Type, By Therapeutics Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球细胞激素市场价值为 952.3 亿美元，预计将大幅扩张，到 2030 年达到新的高度，预计复合年增长率为 7.82%。细胞激素——参与免疫系统调节、发炎和细胞间通讯的关键讯号蛋白——已成为治疗创新和疾病管理的关键。

市场概览
预测期 2026-2030
2024年市场规模 952.3亿美元
2030年市场规模 1499.5亿美元
2025-2030 年复合年增长率 7.82%
成长最快的领域 癌症
最大的市场 北美洲

细胞激素生物学的持续进步正在开启癌症、自体免疫和传染病领域的新临床应用。全球慢性病盛行率的激增推动了基于细胞因子的疗法的开发和应用，为市场持续成长奠定了基础。

在不断增长的研发投资和精准医疗计画的支持下，治疗创新正在将细胞激素疗法转变为现代治疗方案的组成部分。对生物製剂和个人化医疗保健解决方案的日益依赖进一步推动了生物製药和生物技术行业的产品开发。随着临床应用的扩大和产业关注度的提高，细胞激素市场将在未来几年迎来动态发展。

关键市场驱动因素

研发（R&D）的策略重要性

2023年，美国生技製药公司在研发方面投资近960亿美元，凸显了该产业对创新的承诺。这种关注导致了：

开发具有更高安全性和有效性的突破性细胞激素疗法

增强提供差异化解决方案的公司的竞争地位

投资者和策略伙伴的兴趣日益浓厚

更广泛的临床用途，进而扩大市场潜力

主要市场挑战

安全性和不良反应

主要安全相关问题包括：

长期临床试验以确定安全剂量和治疗参数

可能影响治疗采用和患者信任的不良反应风险

加强监管，可能会延迟审批并增加合规负担

为了解决这些问题，公司正在投资：

临床前模型与高阶体外研究

临床试验期间的全面安全监控

继续研究分子机制以增强靶向性并最大限度地减少副作用

主要市场趋势

个人化细胞激素疗法的出现

细胞激素治疗领域正在经历向个人化医疗的显着转变。透过利用生物标记和基因分析，个人化细胞激素治疗可提供：

透过有针对性的介入改善治疗效果

透过针对患者的给药策略减少不良反应

提高生物製剂在主流治疗方案的接受度

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球细胞激素市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依细胞激素类型（肿瘤坏死因子-TNF、白血球介素-Il、干扰素-IFN、表皮生长因子-EGF、其他）
    • 依治疗应用（癌症、气喘及呼吸道发炎、关节炎、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美细胞激素市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲细胞激素市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章：亚太细胞激素市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美细胞激素市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲细胞激素市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章：全球细胞激素市场：SWOT 分析

第 14 章：竞争格局

  • GlaxoSmithkline PLC
  • Novartis AG
  • Amgen Inc
  • Pfizer Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Biocon Limited
  • Abbvie Inc
  • Johnson and Johnson
  • UCB SA

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 16140

The Global Cytokine Market was valued at USD 95.23 billion in 2024 and is expected to witness significant expansion, reaching new heights by 2030 with a projected CAGR of 7.82%. Cytokines-key signaling proteins involved in immune system regulation, inflammation, and intercellular communication-have become pivotal in both therapeutic innovation and disease management.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 95.23 Billion
Market Size 2030USD 149.95 Billion
CAGR 2025-20307.82%
Fastest Growing SegmentCancer
Largest MarketNorth America

Ongoing advancements in cytokine biology are unlocking novel clinical applications across cancer, autoimmune, and infectious diseases. The surge in chronic illness prevalence globally has driven the development and uptake of cytokine-based therapies, positioning the market for sustained growth.

Therapeutic innovations, supported by growing R&D investments and precision medicine initiatives, are transforming cytokine therapies into integral components of modern treatment protocols. Increasing reliance on biologics and personalized healthcare solutions is further fueling product development across biopharmaceutical and biotechnology industries. With expanding clinical use and heightened industry focus, the cytokine market is poised for dynamic evolution in the years ahead.

Key Market Drivers

Strategic Importance of Research and Development (R&D)

R&D remains a fundamental catalyst for growth in the cytokine market. As the biological complexity of cytokines becomes better understood, new opportunities for drug development and therapeutic application continue to emerge.

In 2023, U.S. biopharmaceutical firms invested nearly USD 96 billion in R&D, underlining the industry's commitment to innovation. This focus has led to:

Development of breakthrough cytokine therapies with improved safety and efficacy profiles

Strengthened competitive positioning for companies offering differentiated solutions

Heightened interest from investors and strategic collaborators

Broader clinical use, thereby expanding the market potential

Robust R&D pipelines, along with strategic collaborations between research institutions and industry stakeholders, are expected to further accelerate the development of targeted cytokine therapies.

Key Market Challenges

Safety and Adverse Effects

The therapeutic use of cytokines presents inherent challenges due to their potent biological activity. While effective, cytokines can produce complex and, at times, unpredictable physiological responses.

Major safety-related issues include:

Prolonged clinical trials to establish safe dosing and treatment parameters

Risk of adverse effects that may affect treatment adoption and patient trust

Heightened regulatory oversight, which may delay approvals and increase compliance burdens

To address these concerns, companies are investing in:

Preclinical models and advanced in vitro studies

Comprehensive safety monitoring during clinical trials

Continued research into molecular mechanisms to enhance targeting and minimize side effects

Key Market Trends

Emergence of Personalized Cytokine Therapies

The cytokine therapy landscape is witnessing a notable shift toward personalized medicine. By leveraging biomarkers and genetic profiling, personalized cytokine treatments offer:

Improved therapeutic outcomes through targeted intervention

Reduced adverse effects via patient-specific dosing strategies

Enhanced acceptance of biologics in mainstream treatment regimens

Pharmaceutical developers are increasingly investing in companion diagnostics, biomarker discovery, and niche formulations to align with this trend. These developments are reshaping therapeutic strategies and enabling a patient-centric approach, which is expected to be a significant market differentiator moving forward.

Key Market Players

  • GlaxoSmithKline PLC
  • Novartis AG
  • Amgen Inc
  • Pfizer Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Biocon Limited
  • Abbvie Inc
  • Johnson and Johnson
  • UCB S.A

Report Scope:

In this report, the Global Cytokine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cytokine Market, By Cytokine Type:

  • Tumour Necrosis Factor-TNF
  • Interleukins-Il
  • Interferons-IFN
  • Epidermal Growth Factor-EGF
  • Other

Cytokine Market, By Therapeutics Application:

  • Cancer
  • Asthma and Airway Inflammation
  • Arthritis
  • Other

Cytokine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cytokine Market.

Available Customizations:

Global Cytokine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cytokine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cytokine Type (Tumour Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other)
    • 5.2.2. By Therapeutics Application (Cancer, Asthma and Airway Inflammation, Arthritis, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Cytokine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cytokine Type
    • 6.2.2. By Therapeutics Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cytokine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cytokine Type
        • 6.3.1.2.2. By Therapeutics Application
    • 6.3.2. Canada Cytokine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cytokine Type
        • 6.3.2.2.2. By Therapeutics Application
    • 6.3.3. Mexico Cytokine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cytokine Type
        • 6.3.3.2.2. By Therapeutics Application

7. Europe Cytokine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cytokine Type
    • 7.2.2. By Therapeutics Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cytokine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cytokine Type
        • 7.3.1.2.2. By Therapeutics Application
    • 7.3.2. United Kingdom Cytokine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cytokine Type
        • 7.3.2.2.2. By Therapeutics Application
    • 7.3.3. Italy Cytokine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Cytokine Type
        • 7.3.3.2.2. By Therapeutics Application
    • 7.3.4. France Cytokine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cytokine Type
        • 7.3.4.2.2. By Therapeutics Application
    • 7.3.5. Spain Cytokine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cytokine Type
        • 7.3.5.2.2. By Therapeutics Application

8. Asia-Pacific Cytokine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cytokine Type
    • 8.2.2. By Therapeutics Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cytokine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cytokine Type
        • 8.3.1.2.2. By Therapeutics Application
    • 8.3.2. India Cytokine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cytokine Type
        • 8.3.2.2.2. By Therapeutics Application
    • 8.3.3. Japan Cytokine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cytokine Type
        • 8.3.3.2.2. By Therapeutics Application
    • 8.3.4. South Korea Cytokine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cytokine Type
        • 8.3.4.2.2. By Therapeutics Application
    • 8.3.5. Australia Cytokine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cytokine Type
        • 8.3.5.2.2. By Therapeutics Application

9. South America Cytokine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cytokine Type
    • 9.2.2. By Therapeutics Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cytokine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cytokine Type
        • 9.3.1.2.2. By Therapeutics Application
    • 9.3.2. Argentina Cytokine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cytokine Type
        • 9.3.2.2.2. By Therapeutics Application
    • 9.3.3. Colombia Cytokine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cytokine Type
        • 9.3.3.2.2. By Therapeutics Application

10. Middle East and Africa Cytokine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cytokine Type
    • 10.2.2. By Therapeutics Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cytokine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cytokine Type
        • 10.3.1.2.2. By Therapeutics Application
    • 10.3.2. Saudi Arabia Cytokine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cytokine Type
        • 10.3.2.2.2. By Therapeutics Application
    • 10.3.3. UAE Cytokine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cytokine Type
        • 10.3.3.2.2. By Therapeutics Application

11. Market Dynamics

  • 11.1. Driver
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Cytokine Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. GlaxoSmithkline PLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. Amgen Inc
  • 14.4. Pfizer Inc.
  • 14.5. Sanofi SA
  • 14.6. AstraZeneca plc
  • 14.7. Biocon Limited
  • 14.8. Abbvie Inc
  • 14.9. Johnson and Johnson
  • 14.10. UCB S.A

15. Strategic Recommendations

16. About Us & Disclaimer